Alivus Life Sciences Ltd (ALIVUS) Q3FY25 Concall Summary - Dec-2024 Qtr
Performance Overview
- Glenmark Life Sciences reported strong revenue growth of 12% YoY and 27% QoQ, reaching 642 crores. This growth was fueled by both GPL and non-GPL businesses, with the generic business showing a 16.9% YoY increase.
- Geographically, India, Europe, ROW, and Japan were the key drivers of this growth. The company recovered some Q2 spillover revenue, with further recovery expected in Q4.
- CDMO business exhibited encouraging sequential growth of 25%, though YoY growth was subdued due to cyclical demand.
- Gross margin stood at 55.6%, aligning with previous guidance. EBITDA margin improved to 31.3%, up 90 basis points YoY and 310 basis points QoQ, attributed to a better product mix and stable expenses.
- The company maintains a robust pipeline with over 548 DMF and CEP filings globally. The high-potent API pipeline, representing a significant market opportunity, continues to progress, with 21 products in various development stages.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.